A hormone treatment called tesamorelin lowers liver fat by 2.9% more than a placebo in people with HIV who have excess abdominal fat after six months of treatment.

For people with HIV and fatty liver disease on INSTI drugs, tesamorelin likely reduces liver fat by 4.9% while placebo has almost no effect (0.1% decrease) after a year.

When belly fat decreases in people with HIV, liver fat also tends to decrease, showing a connection between these two types of fat.

People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.

For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 4.9% compared to a tiny 0.1% reduction in those on a placebo.